Background: Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV)
| INTRODUCTION
Both HIV and hepatitis C (HCV) infections have been associated with a higher risk of diabetes mellitus (DM), but results are conflicting. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In HIV-infected patients, insulin resistance (IR) and DM have been related to lipodystrophy and exposure to the first generation of protease inhibitors (PI) or to D-thymidine nucleoside analogues and didanosine. 1, 13 In HCV-infected patients, apart from cirrhosis from any cause, which is a well established risk factor for IR and DM, it has been suggested that HCV infection could directly induce IR and DM by interfering with glucose metabolism. 14 In addition, DM has been observed as a side effect during or after interferon (IFN)-based HCV therapy. [15] [16] [17] Furthermore, a decrease in IR and in the incidence of DM has been observed in HCV-treated patients who achieved sustained viral response (SVR), but results are conflicting. [18] [19] [20] [21] The aim of this study was to determine whether there is an association between chronic hepatitis C and the incidence of DM, and to study the role of factors such as cirrhosis, IFN-based HCV therapy, SVR and chronic hepatitis B infection among patients living with HIV (PLHIV) followed in a large French multicentre cohort in the combination antiretroviral therapy (cART) era (from January 2000 to July 2013).
| ME TH ODS
Dat'AIDS is a French multicentre prospective cohort involving 12
large HIV reference centres in France. 22 and alanine aminotransferase levels, and platelet count) as a different non-invasive marker of liver fibrosis. 23 We used a cut-off value of >3.25 to determine a high probability of advanced fibrosis as previously published. 
| Statistical analysis
After checking for data consistency, we conducted a descriptive analysis of the database: continuous variables are expressed as mean AE SD, and categorical variables as number and percentage.
Cox models for survival analysis were used to study the time to occurrence of DM. The lifetime was defined as the time between the date of HIV diagnosis and the date of DM diagnosis. For patients who were lost to follow-up or patients who died before occurrence of DM, data were censored at the date of the last follow-up visit. Univariate Cox models were used to identify factors associated with DM. Factors with a P value <0.20 by univariate analyses (Wald Chi-squared test) were included in a multivariate extended Cox model built using a manual backward elimination procedure. All Cox models were systematically adjusted for calendar year of HIV diagnosis. The statistical significance level was set at P < 0.05, and all significance tests were 2-sided. All statistical analyses were performed using SAS software version 9.4 (SAS Institute
Inc., Cary, NC, USA). By univariate analysis ( 
| RESULTS

Between
| DISCUSSION
In this large French multicentre cohort of over 28 000 PLHIV, prospectively followed for a mean duration of 12.4 AE 7.9 years, 969 patients (3.4%) developed DM within a mean time of 11.0 AE 6.4 years, giving a rate ratio of DM of 2.74 cases per 1000
person-years of follow-up (95% CI 2.57-2.91). As in the non-HIV population, older age, elevated BMI and cirrhosis were found to be predictors of DM in our population. However, chronic hepatitis C per se, the duration of chronic hepatitis C, and a history of IFNbased HCV therapy were not found to be associated with an increased risk of DM. Furthermore, in a sub-analysis restricted to HIV/HCV coinfected patients, SVR was also not found to be statistically related to DM.
Our study presents several strengths. First, it provides data from a large nationwide prevalent cohort of over 28 000 PLHIV followed in routine practice in France, with a long duration of HIV in the overall cohort and a long duration of chronic HCV infection in HIV/HCV coinfected patients, enabling identification of any long-term impact of chronic HCV infection on DM occurrence. Moreover, the number of events is large, thus conferring high statistical power on the results.
Secondly, for the evaluation of the impact of hepatitis C on the risk of DM, our study includes only patients with chronic hepatitis C infection, and evaluates also in the same analysis major HCV covariates such as the duration of HCV infection, cirrhosis, history of IFN-based therapy and SVR, which are all potentially associated with DM.
Thirdly, the methodology and the statistical methods used are robust and appropriate. Indeed, we used proportional risk models, and timedependent variables. Therefore, despite a higher prevalence of DM among human immunodeficiency virus/hepatitis C virus coinfected patients, duration of chronic hepatitis C was not associated with time to DM in our Cox-extended model. To the best of our knowledge, this is the first study to evaluate the duration of HCV infection as a timedependent variable. In contrast, most studies that found an association between hepatitis C and DM included all patients with positive HCV serology, notably without excluding patients with HCV spontaneous cure, who represented 16% in our cohort. Furthermore, previous studies did not simultaneously analyse cirrhosis, which is a well-established risk factor of DM and/or the duration of HCV infection. 2, 3, 11, 12, 24 In an Italian cohort of 6505 PLHIV, chronic hepatitis C and positive HCV serology were both evaluated, but not cirrhosis, 24 and chronic hepatitis C but not positive HCV serology was associated with incident and prevalent DM. 24 Furthermore, our results are in line with a United
States population-based study reporting that DM was not associated with positive HCV serology or with chronic hepatitis C. 8 Our results
are also in keeping with other published data performed among PLHIV. 1, 4, 5, 21, 25, 26 DM has been observed in around 30% of patients with cirrhosis of any cause. 27 The pathophysiology of DM in cirrhotic patients includes IR present in 35%-80% of patients with cirrhosis, even at early stages; hyperinsulinemia, due to decreased extraction of insulin by a damaged liver; the presence of portosystemic shunts, and may be potentiated by increased levels of counter-insulin hormones such as glucagon, growth hormone and several cytokines. 27, 28 In our study, patients with cirrhosis were twice as likely to develop DM. In a French HIV/HCV coinfected cohort, DM was also more frequent in patients with advanced liver fibrosis (10.5% vs 3.1%, P < 0.0001). 29 In line with our results, several studies have found that liver damage, but not HCV status is associated with a higher risk of DM. 8, 26 As in the US population, elevated alanine aminotransferase and gamma glutamyltransferase activities were associated with DM regardless of HCV status. 8 In a cohort study in Southern Italy, an association between positive HCV serology and a higher incidence of DM in the following 20 years was observed only in the subgroup of patients with elevated alanine aminotransferase. Although a history of IFN therapy was reported in high number of patients (n = 2010; 7%), this factor was also not related to DM.
In HIV seronegative patients, no increase in the risk of DM attributable to chronic hepatitis B without cirrhosis has been reported. 37, 38 However, HBV-related cirrhosis is an independent risk factor for DM. 37 Among PLHIV, the impact of chronic hepatitis B on occurrence of DM has been poorly evaluated. In the Swiss HIV cohort, in line with our results, evidence regarding an association with chronic hepatitis B was inconclusive. 4 In recent studies, the prevalence of DM in PLHIV was reportedly comparable to the general population of similar age. 39, 40 In our cohort, among HIV related factors, AIDS status, a low nadir CD4 cell count (≤200/mm 3 ) and a detectable HIV viral load were independently associated with a higher risk of DM. These factors are related to the severity of immunodepression, which has been associated with IR. 41 These factors have also been found to be predictors of DM in other cohorts. 4, 6, 42 After the introduction of first generation nucleoside reverse transcriptase inhibitors (NRTI) and PIs, various cohorts observed an increased incidence of DM at the end of 90's. 1, 40 In a French cohort, the incidence of DM peaked in 1999-2000 and decreased markedly thereafter. 1 In a Danish nationwide population-based cohort study, PLHIV had no increased risk of DM compared to the general population after the year 1998; in contrast, in the years 1996-1998, the risk of DM was increased irrespective of cART treatment. 40 Exposure to PIs, stavudine, didanosine and zidovudine has been associated with an increased risk of DM. 1, 4, 7, 26, 40 In our study, a longer duration of cART was predictive of a lower risk of DM, but overall PI use was related to DM occurrence.
This study has some limitations. The major limitation concerns the high level of missing data on ethnicity, precluding evaluation of this variable. Indeed, the prevalence of DM may differ according to ethnicity. 43, 44 The second limitation concerns the identification of patients with DM. These patients were identified by the presence of ICD-10 codes, and assumed that the diagnoses were correctly established by clinicians. However, the prevalence of DM in our cohort (3.4%) was comparable to other European cohorts, with a prevalence estimated at 3%-4%. 24 47, 48 Therefore, prospective studies should be conducted to assess the impact of early treatment of HCV infection, and of high rates of SVR with DAA treatments, on the occurrence of DM. 49 In conclusion, our study shows that in PLHIV, cirrhosis is associated with an increased risk of DM, but not chronic HCV infection or duration of HCV infection. Furthermore, in the late cART era, the duration of cART was no longer associated with a higher risk of DM.
Apart from HIV factors related to immunodeficiency (AIDS status, low nadir CD4 cell count and detectable HIV viral load), PLHIV share the same traditional risk factors for DM, such as age and BMI, as compared to the general population.
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